Insider · CIK 0001855980

Secora Michael

Reports to the SEC for 2 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001855980

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-16	IAMIambic Therapeutics, Inc. · Series B-3 Convertible Preferred StockC Conversion	CFO & Chief Corp Dev Ofcr	CConversion	−61.3K sh	—	—	0
2026-10-16	IAMIambic Therapeutics, Inc.C Conversion	CFO & Chief Corp Dev Ofcr	CConversion	+61.3K sh	—	—	279,902
2026-10-14	IAMIambic Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	CFO & Chief Corp Dev Ofcr	AAward	+170K sh	—	—	170,300
2026-10-14	IAMIambic Therapeutics, Inc.A Award	CFO & Chief Corp Dev Ofcr	AAward	+28.4K sh	—	—	218,560
2024-11-15	RXRXRECURSION PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−11.9K sh	$6.17	−$73.7K	1,487,694
2024-11-13	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,514,631
2024-11-13	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$7.66	−$115K	1,499,631
2024-11-13	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	337,635
2024-11-12	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,490,256
2024-11-12	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	377,010
2024-11-12	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$7.64	−$115K	1,475,256
2024-10-09	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$6.36	−$95.4K	1,450,881
2024-10-09	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,465,881
2024-10-09	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	416,385
2024-10-08	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$6.32	−$94.8K	1,426,506
2024-10-08	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,441,506
2024-10-08	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	455,760
2024-09-11	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$6.32	−$94.7K	1,402,131
2024-09-11	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,417,131
2024-09-11	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	495,135
2024-09-10	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$6.17	−$92.5K	1,377,756
2024-09-10	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,392,756
2024-09-10	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	534,510
2024-08-15	RXRXRECURSION PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−12K sh	$6.69	−$80K	1,353,381
2024-08-14	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$6.35	−$95.3K	1,365,343
2024-08-14	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	573,885
2024-08-14	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,380,343
2024-08-13	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,355,968
2024-08-13	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$6.35	−$95.2K	1,340,968
2024-08-13	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	613,260
2024-07-10	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	652,635
2024-07-10	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$7.24	−$109K	1,316,593
2024-07-10	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,331,593
2024-07-09	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$7.32	−$110K	1,292,218
2024-07-09	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,307,218
2024-07-09	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	692,010
2024-06-14	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	731,385
2024-06-14	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$9.27	−$139K	1,267,843
2024-06-14	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,282,843
2024-06-13	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−39.4K sh	—	—	770,760
2024-06-13	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−15K sh	$9.32	−$140K	1,243,468
2024-06-13	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+39.4K sh	$2.22	+$87.4K	1,258,468
2024-05-15	RXRXRECURSION PHARMACEUTICALS, INC.F Tax Payment	Chief Financial Officer	FTax Payment	−12K sh	$10.01	−$120K	1,219,093
2024-04-17	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−37.5K sh	—	—	810,135
2024-04-17	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+37.5K sh	$2.22	+$83.3K	1,254,179
2024-04-17	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−23.1K sh	$7.58	−$175K	1,231,055
2024-04-16	RXRXRECURSION PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−25K sh	$7.67	−$192K	1,216,679
2024-04-16	RXRXRECURSION PHARMACEUTICALS, INC. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−37.5K sh	—	—	847,635
2024-04-16	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+37.5K sh	$2.22	+$83.3K	1,241,679
2024-03-13	RXRXRECURSION PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+37.5K sh	$2.22	+$83.3K	1,229,179

Recent filings

Accepted (ET)
Oct 19 19:514
Secora Michael0001855980-26-000009
SEC(opens sec.gov)
Oct 16 16:164
Secora Michael0001855980-26-000007
SEC(opens sec.gov)
Nov 194
Secora Michael0001601830-24-000214
SEC(opens sec.gov)
Nov 144
Secora Michael0001601830-24-000204
SEC(opens sec.gov)
Oct 104
Secora Michael0001601830-24-000176
SEC(opens sec.gov)
Sep 124
Secora Michael0001601830-24-000156
SEC(opens sec.gov)

Companies

Address

C/O IAMBIC THERAPEUTICS, INC. 5627 OBERLIN DRIVE, SUITE 120

SAN DIEGO, CA, 92121